Ascentage Pharma Group Corporation

Sionna Therapeutics has multiple drug candidates in the clinic and an ambition to improve cystic fibrosis treatment beyond what Vertex Therapeutics has achieved with its blockbuster portfolio of cysti

If biopharma companies keep up the pace of three initial public offerings in the US per month seen in January, the number of IPOs in 2025 will exceed the 25 first-time offerings that drug developers a

Maryland- and Suzhou, China-headquartered Ascentage Pharma became the first biopharmaceutical firm to complete an initial public offering in the US in 2025, pricing 7.33 million American depositary sh

Throughout 2024 and against persistent financial headwinds, novice and returning sole Chinese company sponsors of clinical trials initiated a total of seven new global Phase III programs that included